Key facts
as of Sep 2026- Biogenera’s last known valuation is $87.9M.
- It has raised $15.1M; the latest was Equity Crowdfunding ($1.7M) in Jun 2024.
- Notable investors include Corrado Tirassa, Embed Capital, FocusFuturo, Investinit, Italian Angels for Growth — 9 tracked in total.
- 5 institutional filers report fund marks on Biogenera across 26 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Biogenera
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Biogenera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
5 filers · latest Jun 20265 SEC-registered funds reported 26 fair-value marks on Biogenera between May 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Biogenera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biogenera
Developer of therapeutic drugs designed to provide treatment for pediatric cancer. The company's platform can identify and develop new drugs targeted at each specific therapeutic target consisting of a single mutated gene considered causal for a disease, enabling patients to begin treatment more quickly and resulting in a higher likelihood of successful treatment.
- Sector
- Healthcare
- HQ
- Bologna, Italy
- Founded
- 2008
- Employees
- 18
- Website
- biogenera.com/
- Ownership
- Privately Held (backing)